Influvac is a trivalent inactivated influenza virus vaccine based on isolated surface antigens of A and B strains of myxo-virus influenza.

For the 2007/2008 season, one inoculation dose of 0.5 ml on the basis of the WHO recommendations contains hemagglutinin and neuraminidase equivalent to:

A/Wisconsin/67/2005 (H3N2)-like strain (A/Wisconsin/67/2005 NYMCX-161-B reass.) (15 µg haemagglutinin/dose) A/Solomon Islands/3/2006 (H1N1)-like strain (A/Solomon islands/3/2006 IVR-145 reass.) (15 µg haemagglutinin/dose) B/Malaysia/2506/2004-like strain (B/Malaysia/2506/2004) (15 µg haemagglutinin/dose)

 

Prevention of influenza, particularly for high-risk groups and patients over the age of 65 years

 

Hypersensitivity to the active substances, to any of the excipients and to eggs, chicken protein, formaldehyde, cetyltrimethylammonium bromide, polysorbate 80, or gentamicin. Immunisation shall be postponed in patients with febrile illness or acute infection.

 

Influvac 2007/2008 as far as is known can be used as directed without danger to the foetus in pregnancy and during lactation.

 

Influvac 2007/2008 as far as is known can be used as directed without danger to the foetus in pregnancy and during lactation.

 

The dose for adults and children is 0.5 ml (for details see package insert).Immunization should be carried out every autumn by intramuscular or deep subcutaneous injection.

Protection is generally obtained within 14 days following the injection. The duration of the post-vaccinal immunity varies but is usually 6-12 months.

 

Local Side Effects:

• Most Commonly: redness (particularly after subcutaneous injection), swelling and pain.
• Rarely: swelling of the lymph glands in the vicinity of the injection site.

Systemic Side Effects:

• Most Commonly: fatigue, headache, sweating, trembling, rises in temperature, myalgia, arthralgia or gastrointestinal symptoms.
  These symptoms generally disappear without treatment within 1-2 days.
• Rarely: neuralgia, paraesthesia, convulsions, transient thrombocytopenia, sometimes with hemorrhaging and formation of hematomas, pericarditis.
  Inflammatory reactions of the central and peripheral nervous system, ranging from increasing paralysis to respiratory paralysis, for example Guillain Barré syndrome. Allergic reactions, which only lead to shock in very rare cases. Reactions can also occur following intravascular injection which can develop to shock. Vasculitis has been reported in very rare cases, occurring within 2 weeks following immunization. This may be coupled with temporary renal problems.

 

for PDF files, a free viewer is downloadable on the Adobe Systems' World Wide Website